Replies to post #119824 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

This is really important because the scientific community doesn't really agree on a specific diagnosis of "Alzheimer's".

These are drugs that may intervene on markers that are relevant across many different disease subtypes. We may, for example, want to evaluate these different targets simultaneously, as part of one large study. This could give us a better way to understand the comparative benefits of a drug across different settings. To enable these master protocols, it’s often important to do molecular patient screening. This can lead to the development of a diagnostic that can also be used to guide patient care.